Rockwell Medical, Inc. — FY 2014 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2014; fourth-quarter figures are also noted below. Rockwell manufactured and sold hemodialysis concentrates and ancillary products, which generated over 89% of 2014 revenue. Triferic and Calcitriol were not yet commercially launched during the reporting year. The FDA approved Triferic in January 2015, after year-end; the company planned to launch both drugs in 2015.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Sales | $54.2 million | $52.4 million |
| Gross profit / margin | $8.5 million / 15.8% | $6.7 million / 12.7% |
| Operating loss | $17.6 million | $47.1 million |
| Net loss | $21.3 million; $0.52 per share | $48.8 million; $1.48 per share |
| Operating cash flow | $4.3 million | $(50.7) million |
- Sales increased 3.5%; domestic sales grew 2.5% and international sales 10.4%. Gross profit rose 28.3%, reflecting a more favorable product mix, including greater CitraPure volume, and lower operating and distribution costs.
- Research and product development expense fell to $7.8 million from $39.4 million, principally following completion of Triferic’s Phase 3 program. SG&A increased to $18.3 million from $14.3 million, including higher equity compensation and Triferic-related marketing, legal and regulatory costs.
- Net interest expense was $3.8 million; total interest expense was $4.2 million. The company repaid its high-cost loan in December 2014 and reported no debt at year-end.
- Year-end cash and cash equivalents were $65.8 million and available-for-sale investments were $19.9 million. Current assets were $94.7 million, current liabilities $9.8 million, and working capital $84.9 million. Total assets were $98.0 million.
- Operating cash flow included the $20 million Baxter upfront payment, of which $19.5 million remained deferred as license revenue at year-end. Thus, 2014 operating cash flow should not be read as solely recurring operating generation.
- The company raised approximately $55 million net in a public offering, sold $15 million of shares to Baxter, and received $8.4 million from warrant exercises. Shares outstanding increased to 50.3 million from 40.1 million; shareholders’ equity was $68.7 million versus $0.6 million.
Fourth-quarter 2014
Sales were $14.45 million versus $13.96 million in Q4 2013; gross profit was $2.58 million versus $2.06 million. Operating loss was $5.02 million versus $7.53 million, and net loss was $6.38 million versus $8.33 million. Q4 2014 net loss per share was $0.14 versus $0.21.
Material changes, outlook and risks
- Baxter distribution agreement: Signed in October 2014 for an initial 10-year term, Baxter became the exclusive distributor for concentrate and ancillary products in the U.S. and certain foreign markets. The agreement excludes drug products. Rockwell expects lower operating costs and potentially improved operating profit, while acknowledging sales will initially decline as the distribution model changes. Baxter’s $20 million upfront fee is recognized over the agreement based on shipments.
- Baxter agreed to provide up to $10 million toward a new Western U.S. manufacturing facility, subject to terms and timing. The filing says the fee was agreed, not that the full amount had been received by year-end. Certain termination, regulatory, litigation, or other trigger events could require partial repayment of the upfront and facility fees.
- Management expected to launch Triferic and Calcitriol in 2015, anticipated positive operating cash flow following drug launches, and expected profitability after launch. These are forward-looking expectations, not reported results or quantified earnings guidance. Management said 2015 R&D spending was not expected to be significant.
- Triferic’s clinical studies showed maintenance of hemoglobin and, in the PRIME study, lower ESA use; these trial findings do not establish commercial adoption or realized cost savings. Commercial success depends on provider acceptance, reimbursement, safety, manufacturing and competition.
- Customer concentration is significant: DaVita accounted for 49% of sales in each of 2012–2014. The dialysis market is also exposed to government reimbursement changes and pricing pressure. Baxter may terminate in specified circumstances, and its minimum purchase requirements support exclusivity.
- The company reported ordinary-course legal proceedings, whose resolution management did not expect to materially affect the financial statements; the filing does not provide a clear quantified exposure. It reported effective disclosure controls and internal control over financial reporting, with an unqualified auditor opinion.
Important facts for investors to verify
- Whether Triferic and Calcitriol launches achieved adoption, reimbursement coverage, and revenue after the filing date.
- How much of operating cash flow and reported revenue reflects recurring product activity versus Baxter-related deferred-fee recognition.
- Baxter’s purchase volumes, exclusivity status, facility construction and funding milestones, and any potential fee-refund triggers.
- DaVita’s continued relationship and the effect of customer concentration or dialysis-provider consolidation.
- Share dilution, including outstanding options and future equity compensation, and the company’s path from substantial losses to management’s stated profitability outlook.